Covid-19 News

  • I do not understand this sentence. The technology is more than 20 years old. That means the vaccines are more than 20 years old.

    The vaccines now are 1.5 years old. Mass application done since 6 months.

    All RNA vaccines are termed experimental. Normally you are not allowed to generate money with experimental drugs. Why does the mafia FDA/EMA BIg Pharma break the law?

    Predictions: People that got the Pfizer vaccine will have more problems fighting the flue. These people also very likely will develop auto immune deficits.

    Pumping several hundred different and unknown RNA fragments into a cell can cause a pletora of reactions.

    Only idiots kill/destroy themselves.

    Further: Some doctors and therapists report strange reactions after treating RNA vaccinated patients. So far this is anectdotic. Keep eyes open.

    If you need a vaccine the use Astra Zenca or J&J. Sputnik has quality problems.

  • Jed if you read they have used MRNA vaccines on any humans before 2020, I'd really like to read that study as I haven't been able to find these studies.

    As noted by Alan Smith and also:


    Coronavirus vaccine development: from SARS and MERS to COVID-19

    Various forms of vaccines targeting SARS-CoV and MERS-CoV have been developed and tested in preclinical models. However, only a few of them entered clinical trials and none of them have been FDA approved. These approaches include protein subunit vaccines, virus-like particle vaccines, DNA vaccines, viral vector vaccines, whole-inactivated vaccines and live-attenuated vaccines.

    (I recall reading that some of these included mRNA vaccines.)

  • FDA has approved the Biontech for adolescents..follow the blind science.. and the money..

    Francis Collins.."safe and effective" ;(…o-normal.html?jwsource=cl

    To quote Dr. Francis Collins, Director of the NIH (in a way Fauci's boss) from that video:

    "Let these kids from 11 to 15 start to take advantage of the Pfizer dose, a two dose vaccine, which was shown in this trial, which FDA has been looking at, not just to be good, but to be one hundred percent effective and totally safe. So, hard to beat that!"

    Well it could also cure pimples and give them great grades and lots of friends.

    Seriously, I quote Collins as a matter of historical record.

  • Dr John update and some ivermectin update

    External Content
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

  • National news outlet finally beginning to call out the CDC . Ivermectin next?

    CDC risk of coronavirus transmission outdoors greatly exaggerated, bombshell report finds

    10% benchmark is based 'partly on a misclassification' of some transmission, report claims…ly-exaggerated-report.amp

    A stunning New York Times report claims that the Centers for Disease Control and Prevention's estimate that the risk of coronavirus transmission while outdoors is around 10% is greatly exaggerated.

    The CDC has cited the estimate to back up its recommendation that vaccinated individuals do away with masks in certain outdoor situations, but should keep wearing masks during others.

    According to the Times, the 10% benchmark is based "partly on a misclassification" of some virus transmission in Singapore at various construction sites that may have actually taken place in indoor settings. Singapore also classified settings that were a mix of indoors and outdoors as outdoors, including construction building sites, the outlet reported.

    Still, the number of cases reported at the various sites did not add up to as much as 10% of transmission, but was more like 1% or less, the report stated.

    In a Senate committee hearing on Tuesday, Sen. Susan Collins, R-Maine, pressed CDC director Dr. Rochelle Walensky on the report and said it was one of three recent examples of conflicting, confusing guidance issued by the agency, with the other two involving school reopenings and summer camps.

    Walensky said the 10% benchmark came from a meta-analysis topline result from a study published in the Journal of Infectious Disease back in November.

    "The topline result was less than 10%, published in the Journal of Infectious Diseases, one of our top infectious disease journals," she said. "That is where that came from, it was from a published study that synthesized studies from many places."


    Collins requested that the full report be placed in the record.

    "There are limited data on outdoor transmission," a CDC official told the Times. "The data we do have supports the hypothesis that the risk of outdoor transmission is low. 10 percent is a conservative estimate from a recent systematic review of peer-reviewed papers. CDC cannot provide the specific risk level for every activity in every community and errs on the side of protection when it comes to recommending steps to protect health. It is important for people and communities to consider their own situations and risks and to take appropriate steps to protect their health."

    Multiple officials have said that the CDC will continue to monitor the data in "real time" and make adjustments as needed, including Dr. Anthony Fauci and Walensky. However, critics say the agency’s conservative approach to dropping mask mandates is discouraging some from seeking vaccines.

    We’re at the point right now where we can start lifting these ordinances and allowing people to resume normal activity, certainly outdoors we shouldn’t be putting limits on gatherings anymore, we should be encouraging people to go outside," former FDA commissioner Dr. Scott Gottlieb told CBS’ "Face the Nation" on Sunday. "In the states where prevalence is low, vaccination rates are hgh and we have good testing in place and we’re identifying infections, I think we can start lifting these restrictions indoors as well on a broad basis."

  • Still, the number of cases reported at the various sites did not add up to as much as 10% of transmission, but was more like 1% or less, the report stated.

    If 50'000 spectators stay ass on belly in a soccer stadium (Bergamo - famous hot spot) then may be CDC claimed this has been outdoors...Outdoors means a minimum distance of 1.5 meters where we have 0 transmission or at best get a tiny load. As said out door masks and lock down from 22:00 to 06:00 did kill 3x more people than without.

    In Bergamo 50'000 people touched each other for 2 hours! Far worse than indoors....

    "Let these kids from 11 to 15 start to take advantage of the Pfizer dose, a two dose vaccine, which was shown in this trial, which FDA has been looking at, not just to be good, but to be one hundred percent effective and totally safe. So, hard to beat that!"

    Dr. Francis Collins: One more candidate for the Dr. Mengele award.

    Why not giving the kids free Canabis or LSD? May be they then forget who damaged them.

    Look up all damages in: The EU vaccine report database. Only the > 6000 death are not in there.

  • Rand Paul questions Fauci on gain of function

    External Content
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

  • Did Fauci just lie to a us senator

    NIH Cancels Funding for Bat Coronavirus Research Project

    The abrupt termination comes after the research drew President Trump’s attention for its ties to the Wuhan Institute of Virology.…us-research-project-67486

    Agrant to a New York nonprofit aimed at detecting and preventing future outbreaks of coronaviruses from bats has been canceled by the National Institutes of Health, Politico reports, apparently at the direction of President Donald Trump because the research involved the Wuhan Institute of Virology in China. The virology institute has become a focal point for the idea that SARS-CoV-2 escaped from the laboratory and caused the current COVID-19 pandemic, a scenario experts say is not supported by evidence. Instead, virologists The Scientist has spoken to say the virus most likely jumped from infected animals to humans.

    The grant, first awarded in fiscal year 2014 and most recently renewed last year, went to EcoHealth Alliance, which describes itself as “a global environmental health nonprofit organization dedicated to protecting wildlife and public health from the emergence of disease.” The aims of the funded project included characterizing coronaviruses present in bat populations in southern China and conducting surveillance to detect spillover events of such viruses to people. The project has resulted in 20 publications, most recently a March report on zoonotic risk factors in rural southern China.

    See “Where Coronaviruses Come From”

    EcoHealth Alliance’s partners on the project include researchers at the Wuhan Institute of Virology, a BSL-4 facility that has for months been a focus of conspiracy theories that SARS-CoV-2 escaped or was released from a lab. On April 14, the The Washington Post published a column highlighting State Department cables about concerns regarding safety at the institute. (Experts tell NPR that, even in light of the cables, accidental escape of the virus from a lab remains a far less likely scenario than a jump from animals.)

    Then, in an April 17 White House coronavirus briefing, a reporter, whom Politico identifies as being from Newsmax, falsely stated in a question that “US intelligence is saying this week that the coronavirus likely came from a level 4 lab in Wuhan,” and that the NIH had awarded a $3.7 million grant to the Wuhan lab. “Why would the US give a grant like that to China?” she asked. “We will end that grant very quickly,” Trump said in his answer.

    See “Theory that Coronavirus Escaped from a Lab Lacks Evidence”

    An NIH official then wrote to EcoHealth Alliance to inquire about money sent to “China-based participants in this work,” Politico reports, and the organization’s head, Peter Daszak, responded that a complete response would take time, but that “I can categorically state that no fund from [the grant] have been sent to the Wuhan Institute of Virology, nor has any contract been signed.” Days later, NIH notified EcoHealth Alliance that future funding for the project was canceled, and that it must immediately “stop spending the $369,819 remaining from its 2020 grant”—an unusual move generally reserved for cases of scientific misconduct or financial improprieties, according to Politico.

    In a statement about the cancellation, EcoHealth Alliance says the terminated research “aimed to analyze the risk of coronavirus emergence and help in designing vaccines and drugs to protect us from COVID-19 and other coronavirus threats,” and that it addresses “all four strategic research priorities of the NIH/NIAID Strategic Plan for COVID-19 Research, released just this week.” The organization will, it says, “continue our fight against this and other emerging diseases.”

  • "Indian state of Goa announced it would give the drug to all its adult residents based on an unproven claim that it may help reduce the severity of Covid-19 infections.

    Goa goes for IVM.. WHO advises no. and of course Merck..

    External Content
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.…ganisation-covid-7310664/

  • *sad concerned face* When people were saying that fertility could be affected they were laughed at as some of the worse conspiracy theorists.. up there with flat earthers. Any woman that is pregnant or plans to have children should avoid this until further notice it seems.

  • COVID-19 alters gray matter volume in the brain, new study shows…vid-gray-volume-brain.amp

    COVID-19 patients who receive oxygen therapy or experience fever show reduced gray matter volume in the frontal-temporal network of the brain, according to a new study led by researchers at Georgia State University and the Georgia Institute of Technology.

    The study found lower gray matter volume in this brain region was associated with a higher level of disability among COVID-19 patients, even six months after hospital discharge.

    Gray matter is vital for processing information in the brain and gray matter abnormality may affect how well neurons function and communicate. The study, published in the May 2021 issue of Neurobiology of Stress, indicates gray matter in the frontal network could represent a core region for brain involvement in COVID-19, even beyond damage related to clinical manifestations of the disease, such as stroke.

    The researchers, who are affiliated with the Center for Translational Research in Neuroimaging and Data Science (TReNDS), analyzed computed tomography scans in 120 neurological patients, including 58 with acute COVID-19 and 62 without COVID-19, matched for age, gender and disease. They used source-based morphometry analysis, which boosts the statistical power for studies with a moderate sample size.

    "Science has shown that the brain's structure affects its function, and abnormal brain imaging has emerged as a major feature of COVID-19," said Kuaikuai Duan, the study's first author, a graduate research assistant at TReNDS and Ph.D. student in Georgia Tech's School of Electrical and Computer Engineering. "Previous studies have examined how the brain is affected by COVID-19 using a univariate approach, but ours is the first to use a multivariate, data-driven approach to link these changes to specific COVID-19 characteristics (for example fever and lack of oxygen) and outcome (disability level)."

    The analysis showed patients with higher levels of disability had lower gray matter volume in the superior, medial and middle frontal gyri at discharge and six months later, even when controlling for cerebrovascular diseases. Gray matter volume in this region was also significantly reduced in patients receiving oxygen therapy compared to patients not receiving oxygen therapy. Patients with fever had a significant reduction in gray matter volume in the inferior and middle temporal gyri and the fusiform gyrus compared to patients without fever. The results suggest COVID-19 may affect the frontal-temporal network through fever or lack of oxygen.

    Reduced gray matter in the superior, medial and middle frontal gyri was also present in patients with agitation compared to patients without agitation. This implies that gray matter changes in the frontal region of the brain may underlie the mood disturbances commonly exhibited by COVID-19 patients.

    "Neurological complications are increasingly documented for patients with COVID-19," said Vince Calhoun, senior author of the study and director of TReNDS. Calhoun is Distinguished University Professor of Psychology at Georgia State and holds appointments in the School of Electrical and Computer Engineering at Georgia Tech and in neurology and psychiatry at Emory University. "A reduction of gray matter has also been shown to be present in other mood disorders such as schizophrenia and is likely related to the way that gray matter influences neuron function."

    The study's findings demonstrate changes to the frontal-temporal network could be used as a biomarker to determine the likely prognosis of COVID-19 or evaluate treatment options for the disease. Next, the researchers hope to replicate the study on a larger sample size that includes many types of brain scans and different populations of COVID-19 patients.

  • Strongest Evidence Yet Shows SARS-CoV-2 May Insert Itself Into The Human Genome…tself-into-our-genome/amp

    Our genome is a graveyard littered with genetic fragments of viruses that once plagued our ancestors. If a controversial claim by MIT researchers withstands the criticisms being leveled at it, the virus behind the current pandemic has a fair chance of joining them.

    Having a few chunks of virus code scattered among our genes doesn't necessarily mean the pandemic is here to stay. It could even go some way towards explaining why a handful of patients continue to test positive for COVID-19 long after recovery.

    But SARS-CoV-2 simply isn't equipped with the tools to bury itself in our genetic library, meaning it would need a way to convince our own bodies to manage the job on its behalf.

    "SARS-CoV-2 is not a retrovirus, which means it doesn't need reverse transcription for its replication," says biomedical researcher Liguo Zhang from MIT's Whitehead Institute.

    "However, non-retroviral RNA virus sequences have been detected in the genomes of many vertebrate species, including humans."

    Last year, Zhang and his team shared the initial results of an investigation suggesting SARS-CoV-2 might have a means of accomplishing such a task after all.

    Using published data sets of infected cell cultures and patient samples, the team identified part-human, part-virus transcripts among sequences produced by the cells.

    This was followed by experiments that assessed whether the presence of SARS-CoV-2 particles was enough to stimulate cells into producing certain enzymes that specialize in reverse transcribing RNA into DNA.

    Their findings supported the rather concerning possibility that sequences of the coronavirus could be copied and pasted into our genome; importantly, not everybody in the scientific community was convinced by the evidence.

    Partially due to the fact this research was made publicly available as a preprint before entering the peer-review process, it was met with significant skepticism by other researchers, who also noted the virus-human sequences could simply be artifacts of the very method used to find them.

    Some expressed concerns it could make it harder to ease fears that vaccines based on the virus's code alter our DNA, an argument that might not disprove the results, but does emphasize the value in being certain of your findings before going public.

    The criticisms were fair, as the researchers themselves conceded. So, the team went in search of more robust data to build their case.

    Their work has now gone through peer review and is published in PNAS. In the updated study, the researchers have provided new reasons to think the coronavirus wreaking havoc on our global community might haunt our cells long after the infection is gone.

    In addition to looking for chimeras of coronavirus-human genetic fragments and watching for signs of the virus commandeering transcription tools, the team directly searched for evidence of viral sequences actually inside the human genome.

    They even used three different DNA sequencing techniques to ensure their results weren't an artifact of any one technology.

    In each case, they found fragments of SARS-CoV-2 genetic material slipped into the genetic library of deliberately infected cells, like pages torn from a contraband book.

    The fact that half of the 'pages' were randomly inserted upside down adds weight to the argument that they weren't being inserted deliberately by living viruses.

    On further inspection, the sequences to either side of these rogue elements weren't random pieces of text, either. The coding carried signatures of something called a transposon – a so-called jumping gene that evolved a means for falling out of place and inserting itself back into the genome elsewhere.

    Some transposons manage this through the use of enzymes stolen from past viral infections; hijacked hardware that once used by viruses to edit themselves into a host, but now serve no master but the transposable sequence itself.

    One such class of sequence, called LINE1 retrotransposons, make up a mind-blowing 17 percent of our entire genome. Though most have lost their talent for packing up and moving, some are active enough to still cause the occasional bit of mischief.

    And it could be giving SARS-CoV-2 open access to our DNA.

    "There's a very clear footprint for LINE1 integration," says one of the team, Whitehead Institute biologist Rudolf Jaenisch.

    "At the junction of the viral sequence to the cellular DNA, it makes a 20 base pair duplication."

    However, the fact this work was done in laboratory-infected cell cultures and not actual human hosts still leaves room for doubt. There's also the question of what it means – while the fragments aren't capable of building new infectious particles, it's far from clear whether they might be biologically active in other ways, for good or bad.

    "At this point, we can only speculate," says Jaenisch.

    With so much attention being given to this devastating pandemic, we can be confident that it won't be long before speculations will become solutions that ensure this coronavirus becomes just one more ghost in our bodies' graveyard of plagues.

    This research was published in PNAS.

  • Molnupiravir is considered an antiviral. Ivermectin is not but thought to have anti viral properties. The active ingredient in molnupiravir is taken from ivermectin, by merck. Instead of using ivermectin at let's say $3 a dose, probably much to high, we can use Mercks new molnupiravir at $3000 a dose. Modern medicine shoving right up your arse!

    Lab reveals how an oral antiviral drug confuses the replication machinery of SARS-CoV-2…021-05/uoaf-lrh051121.php

    A University of Alberta virology lab has uncovered how an oral antiviral drug works to attack the SARS-CoV-2 virus, in findings published May 10 in the Journal of Biological Chemistry.

    The researchers demonstrated the underlying mechanism of action by which the antiviral drug molnupiravir changes the viral genome, a process known as excessive mutagenesis or “error catastrophe.”

    “The polymerase, or replication engine of the virus, mistakes molnupiravir molecules for the natural building blocks required for viral genome replication and mixes them in,” explained Matthias Götte, professor and chair of the Department of Medical Microbiology & Immunology in the Faculty of Medicine & Dentistry and member of the Li Ka Shing Institute of Virology. “It causes the polymerase to make sloppy copies—nonsense genomes that are useless and not viable.”

    Molnupiravir is currently in Phase 3 human clinical trials, which are expected to report preliminary data by the end of June. Phase 2 trial results recently revealed that the drug eliminated SARS-CoV-2 infectivity in newly diagnosed patients after five days of treatment.

    The drug is taken as a pill, making it much easier to administer than other approved treatments such as remdesivir or monoclonal antibodies, which must be given intravenously. It has not yet been shown to be effective in treating hospitalized COVID-19 patients with advanced disease, so current trials are focused on determining how well it works for newly diagnosed patients. It is hoped the drug could also be used as a preventive measure to protect household members against infection.

    “Molnupiravir is one of the few compounds under investigation that is orally available,” Götte said. “Data reported so far demonstrate that this drug is well tolerated with no signs of severe side-effects, and it shows an antiviral effect after five days. Whether it can also reduce hospitalizations remains to be seen.”

    “Our work to demonstrate that the effect of the drug is indeed mediated by the viral polymerase is reassuring, because if the drug somehow generates mistakes in the virus and you don’t know how it happens, there could be other mechanisms at work that could also harm the cell,” he said. “Still, the safety of the drug for COVID-19 patients remains to be evaluated and monitored."

    Another step in the hunt for a weapon against future pandemics

    Molnupiravir was first identified as a broad spectrum antiviral at Emory University in Atlanta, Georgia. In 2003 it was developed as a treatment for chronic hepatitis C, but it was dropped due to possible side-effects associated with long-term use. The drug was then tested in humans with influenza, because the course of treatment for flu is much shorter. The focus of testing switched to SARS-CoV-2 after the COVID-19 pandemic emerged. The drug is now being developed in partnership by Merck and Ridgeback Biotherapeutics.

    Merck has made deals with five generic drugmakers in India to make molnupiravir, and at least one of them has applied for approval to use it on an emergency basis, as at least 350,000 new infections are diagnosed in that country every day and vaccination levels are low.

    Götte and his team previously uncovered the mechanisms of action for remdesivir, a now-approved treatment that inhibits replication of the SARS-CoV-2 virus, and baloxavir, an influenza drug.

    Next, they will test molnupiravir’s mechanism of action against the polymerases of some of the other viruses the World Health Organization has identified as having high epidemic potential.

    “All are recognized as emerging pathogens where we need to develop countermeasures,” Götte said. “We need to be prepared with broad-spectrum antivirals that can serve as a first line of defence.”

    “Even once vaccines are developed, we can’t get them into all the arms at once,” he said. “To really fight outbreaks and epidemics, one tool is unlikely to be sufficient.”

    The researchers were supported by grants from the Canadian Institutes of Health Research, the Alberta Ministry of Jobs, Economy and Innovation, and the U.S. National Institutes of Health Centers for AIDS Research. The other authors were graduate student Calvin Gordon and research associate Egor Tchesnokov of the U of A, and Raymond Schinazi of the Emory School of Medicine.

  • Vaccine warriors, spin this!

    WHO reviewing Seychelles COVID-19 data after fully vaccinated people test positive


    The World Health Organization said on Tuesday it was reviewing coronavirus data from Seychelles after the health ministry said more than a third of people who tested positive for COVID-19 in the past week had been fully vaccinated.